#United States #Hematology #Anaheim #Ozelle #O-Cyte 1

Ozelle Launches O-Cyte 1 at ADLM 2026

Ozelle, a key player in hematology diagnostics, made headlines with the launch of its latest automated hematology analyzer, the O-Cyte 1, during the annual ADLM 2026 conference held in Anaheim, California. This groundbreaking device is designed to revolutionize the hematology workflow by combining artificial intelligence (AI) with complete blood morphology (CBM) analysis.

A Step Forward in Hematology

The advent of O-Cyte 1 represents a significant advancement in the company's vision for the future of hematology. This innovative analyzer integrates image-based morphology insights into everyday clinical practices without superseding existing lab expertise. It serves as a complementary tool, adding a new dimension to automated hematology workflows.

Clinical laboratories face the challenge of escalated workloads, increasing the need for more efficient systems that deliver consistent and comprehensive results. The O-Cyte 1 addresses this need through its AI × CBM technology, which enables the transformation of cell images into structured morphological insights. This addition allows for visual cellular evidence to be presented alongside routine hematology results, enhancing diagnostic accuracy and thoroughness.

High Throughput and Flexibility

O-Cyte 1 boasts impressive capabilities, supporting up to 60 tests per hour when operating as a standalone unit. For laboratories with higher demands, the analyzer's design allows for expansion, facilitating up to 360 tests per hour through a cascaded setup. This modular architecture ensures that labs can adjust their capacities according to their workload fluctuations, ensuring streamlined operations.

Furthermore, the compact design of the O-Cyte 1, which includes fluidics contained within consumable components and a service-ready setup, minimizes the daily maintenance burden. This feature enhances its adaptability for deployment across a variety of settings, including hospitals, health screening centers, and regional diagnostic networks.

Comprehensive Hematology Portfolio

In addition to showcasing the O-Cyte 1, Ozelle also presented an expansive portfolio of clinical hematology systems at ADLM 2026. This portfolio features integrated multi-test diagnostic systems that combine hematology, immunoassay, and biochemistry capabilities, underscoring the company's commitment to providing practical and scalable diagnostic solutions across varying testing environments. Their offerings even extend to compact 7-Diff hematology analyzers that incorporate cell imaging and simplified maintenance protocols.

A Vision for Integrated Diagnostics

The O-Cyte 1 launch exemplifies Ozelle's strategic shift from standalone instruments to integrated systems tailored for real-world clinical settings. By merging advanced imaging techniques with AI-powered interpretations, Ozelle aims to foster a healthcare environment where morphology intelligence becomes more accessible and consistent across diverse clinical scenarios.

As the company embarks on this new chapter, they plan to engage collaboratively with laboratories, healthcare organizations, and strategic partners globally to promote the O-Cyte 1 and cultivate further advancements in AI-powered hematology. Those interested in learning more about the product or scheduling a briefing can visit Ozelle's official website for additional information.

Ozelle continues to stand at the forefront of hematology innovation, setting new standards for how blood diagnostics can be performed efficiently and accurately, ultimately improving patient care.